Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022347 | 1.00 | CPB2 (0.40) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL3662433 | 1.00 | CPB2 (0.40) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL2211497 | 0.95 | CPB2 (0.42) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL1039473 | 0.95 | CPB2 (0.42) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL7416589 | 0.95 | CPB2 (0.42) | CPB2MEN1GAAKMT2ATPSAB1 | |
| Ethylenediamine SCHEMBL17669759 | 0.94 | CPB2 (0.41) | CPB2MEN1GAAKMT2ATPSAB1 | |
| Ethylenediamine SCHEMBL17669758 | 0.94 | CPB2 (0.41) | CPB2MEN1GAAKMT2ATPSAB1 | |
| Glycerin SCHEMBL28491442 | 0.92 | CPB2 (0.34) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL20743469 | 0.85 | MEN1 (0.38) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL20743467 | 0.85 | MEN1 (0.38) | MEN1GAAKMT2ATPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-108912201-B | Preparation method of ornithine phytosterol ester hydrochloride | 江南大学 | 2020-12-15 | — | — | CN | claimed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-114980933-B | Compositions and methods for treating viral infections | 奇达拉治疗公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11510992-B1 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220257787-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| EP-4025256-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| CN-108912201-B | Preparation method of ornithine phytosterol ester hydrochloride | 江南大学 | 2020-12-15 | — | — | CN | disclosed |
| CN-108912201-B | Preparation method of ornithine phytosterol ester hydrochloride | 江南大学 | 2020-12-15 | — | — | CN | disclosed |
| CN-111393498-A | Preparation method of water-soluble amino acid phytosterol ester hydrochloride | 广东蔚莱生物科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-2222686-B1 | POLYVIOLOGEN BORONIC ACID QUENCHERS FOR USE IN ANALYTE SENSORS | MEDTRONIC MINIMED INC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-7829341-B2 | Polyviologen boronic acid quenchers for use in analyte sensors | GLUMETRICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2222686-A2 | POLYVIOLOGEN BORONIC ACID QUENCHERS FOR USE IN ANALYTE SENSORS | Glumetrics, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090081803-A1 | POLYVIOLOGEN BORONIC ACID QUENCHERS FOR USE IN ANALYTE SENSORS | GLUMETRICS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009009756-A2 | POLYVIOLOGEN BORONIC ACID QUENCHERS FOR USE IN ANALYTE SENSORS | GLUMETRICS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-4795595-A | Taurine derivatives | FARMITALIA CARLO ERBA S.P.A. (IT) | 1989-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | CPB2 86/4885MEN1 3968/4885GAA 159/4885 |
| US-20090081803-A1 | POLYVIOLOGEN BORONIC ACID QUENCHERS FOR USE IN ANALYTE SENSORS | SLC2A4, SLC2A2, SLC2A1 | CPB2 1453/4885MEN1 1224/4885GAA 249/4885 |
| US-20220257787-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | CPB2 86/4885MEN1 3968/4885GAA 159/4885 |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | CPB2 86/4885MEN1 3968/4885GAA 159/4885 |
| US-11510992-B1 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | CPB2 86/4885MEN1 3968/4885GAA 159/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | CPB2 797/4885MEN1 4679/4885GAA 682/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | CPB2 313/4885MEN1 3799/4885GAA 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.